Entecavir
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Entecavir and local guidelines before prescribing.
Antiviral (HBV)
Mechanism
Guanosine nucleoside analogue inhibiting HBV polymerase.
Uses
Chronic hepatitis B.
Dosing
- Tenofovir (disoproxil 245 mg or alafenamide 25 mg daily) or entecavir (0.5 mg daily) - usually lifelong; cure is rare.
Gastroenterology: Liver disease
Side effects
Headache, fatigue, nausea, lactic acidosis (rare), hepatitis flare on stopping.
Interactions
Nephrotoxic drugs.
Contraindications and cautions
Hypersensitivity
Monitoring
HBV DNA, LFT, renal function
Pregnancy and breastfeeding
Avoid unless essential
Renal and hepatic impairment
Reduce dose if CrCl below 50
Overdose and reversal
Supportive
Special advice
Take on an empty stomach; do not stop abruptly without specialist advice.
More from the textbook: uses, cautions and other points
- Hepatitis B - tenofovir or entecavir (suppress, rarely cure); monitor kidney function and bone with tenofovir disoproxil.
Gastroenterology: Anatomy Physiology Pharmacology - Reactivation: Before chemotherapy, rituximab or other strong immunosuppression, test HBsAg and anti-HBc. Give antiviral prophylaxis (entecavir or tenofovir) if positive - reactivation can cause fatal hepatitis.
Gastroenterology: Liver disease - Tenofovir / entecavir | Chronic hepatitis B; usually long-term; prophylaxis before rituximab or chemotherapy in HBsAg or anti-HBc positive people.
Gastroenterology: Liver disease - Antiviral prophylaxis (entecavir or tenofovir) during and for at least 12–18 months after treatment.
Gastroenterology: Liver disease - Hepatitis B - screen with HBsAg and anti-HBc before rituximab or chemotherapy; antiviral prophylaxis (entecavir or tenofovir) if carrier or anti-HBc positive.
Haematology: Myeloma and Lymphoma - Prophylaxis before immunosuppression - antiviral (e.g. entecavir or tenofovir) if HBsAg positive, or anti-HBc positive before rituximab and similar high-risk treatments, continued for months afterwards.
ID: HIV, viral hepatitis and blood-borne viruses - Entecavir / tenofovir | Chronic hepatitis B - long-term; stopping can cause flares; prophylaxis before rituximab.
ID: HIV, viral hepatitis and blood-borne viruses - Start antiviral prophylaxis (e.g. entecavir) before chemotherapy and continue for months after rituximab finishes (specialist advice).
ID: HIV, viral hepatitis and blood-borne viruses
Where it is discussed in the book
- Gastroenterology: Anatomy Physiology Pharmacology (1 mention)
- Gastroenterology: Liver disease (4 mentions)
- Haematology: Myeloma and Lymphoma (1 mention)
- ID: HIV, viral hepatitis and blood-borne viruses (5 mentions)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (1 mention)
- Microbiology: Virology - structure, replication and important viral infections (3 mentions)